Longeveron (NASDAQ:LGVN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Longeveron (NASDAQ:LGVN) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Longeveron presently has a consensus rating of “Hold” and a consensus price target of $80.00.

Longeveron Stock Up 2.4%

NASDAQ:LGVN opened at $1.71 on Friday. The stock has a fifty day simple moving average of $3.76 and a 200-day simple moving average of $6.59. The company has a market capitalization of $5.45 million, a PE ratio of -0.17 and a beta of -0.19. Longeveron has a 52-week low of $1.31 and a 52-week high of $12.30.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $1.56. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%. The firm had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.33 million. As a group, equities analysts anticipate that Longeveron will post -7.20 earnings per share for the current year.

Institutional Trading of Longeveron

An institutional investor recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC bought a new stake in Longeveron Inc. (NASDAQ:LGVN) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.